Racial and ethnic differences in treatment and survival for hepatocellular carcinoma patients undergoing systemic therapy
Asian and Hispanic patients had the best survival, and Asian patients were more likely to receive novel therapies. As adjustment for many social and clinical factors had minimal impact on these findings, additional research is needed to understand these survival differences.
Authors
- Kelsey S. Lau‐Min (ORCID: https://orcid.org/0000-0001-8854-224X)
- Franklin Iheanacho (ORCID: https://orcid.org/0000-0003-2909-1500)
- Angela C. Tramontano (ORCID: https://orcid.org/0000-0001-5718-6297)
- Thomas A. Abrams (ORCID: https://orcid.org/0000-0003-3101-1573)
- Christopher R. Manz (ORCID: https://orcid.org/0000-0003-0928-3492)
Institutions
- Harvard University (US)
- University of Virginia Health System (US)
- Massachusetts General Hospital (US)
- Dana-Farber Cancer Institute (US)
Publication Details
- Journal
- JNCI Cancer Spectrum
- Published
- 2025-10-11
- DOI
- https://doi.org/10.1093/jncics/pkaf100
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00